Astilbin Chlorogenic Acid Composition for Urinary Infection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Recurrent urinary tract infections, particularly those caused by pathogens like E. coli, often lead to antibiotic resistance due to frequent use, and existing treatments fail to effectively manage inflammation and host defense mechanisms.

Innovation Solution

A composition comprising smilax glabra rhizome extracted astilbin and Flos Lonicerae extracted chlorogenic acid, along with other synergistic ingredients like pathogen isolators, urine pH stabilizers, matrix metalloproteinase inhibitors, and macrophage function modulators, is administered to reduce bacterial adherence, inflammation, and enhance host defense.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are frequently and repeatedly used to treat urinary system infections, then the infection is effectively treated, but antibiotic resistance develops

Engineering Contradiction:
Improveinfection treatment effectivenessVSAvoidantibiotic resistance
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the treatment approach by combining multiple natural compounds with different mechanisms of action (astilbin from Smilax glabra, chlorogenic acid from Flos Lonicerae, urolithin from fruits/nuts, andrographolide from Andrographis paniculata) to treat urinary infections. This multi-component strategy targets bacteria through various pathways simultaneously, reducing the likelihood of resistance development compared to single-antibiotic therapy.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention uses a composite formulation of multiple natural compounds extracted from different plant and food sources. Each component contributes unique anti-infective, anti-inflammatory, and immune-modulating properties, creating a synergistic effect that enhances treatment effectiveness while minimizing resistance induction through diverse mechanisms of action.

Inventive Principle:
Principle #40Composite materials

2Quantity of substance

If conventional treatments focus only on killing bacteria, then bacterial load is reduced, but inflammation and host defense mechanisms are not adequately managed

Engineering Contradiction:
Improvebacterial loadVSAvoidinflammation
Core Design Contradiction:
Quantity of substanceVSObject-generated harmful factors

Solution Approach 1:

The invention employs multi-functional natural compounds that simultaneously perform multiple roles: astilbin and chlorogenic acid exhibit both antibacterial and anti-inflammatory activities; urolithin and andrographolide enhance host immune defense while maintaining anti-infective properties. This universal approach addresses bacterial elimination, inflammation control, and immune support within a single treatment regimen.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The invention merges three critical therapeutic functions into one composition: (1) direct antibacterial action against uropathogens, (2) anti-inflammatory effects to reduce tissue damage and discomfort, and (3) immune system enhancement to improve host defense. This integrated approach comprehensively manages the infection and its associated harmful effects.

Inventive Principle:
Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively reduces the risk of recurrent urethritis and cystitis by inhibiting bacterial adherence, controlling inflammatory responses, and enhancing immune function, offering an alternative to antibiotics that minimizes resistance induction and provides anti-inflammatory benefits.

Implementation Method 1

inhibiting bacterial adherence

Methodology Applied
Scientific EffectBacterial adherence inhibition:

Implementation Method 2

macrophage function modulators

Methodology Applied
Scientific EffectMacrophage function modulation:

Implementation Method 3

matrix metalloproteinase inhibitors

Methodology Applied
Scientific EffectMatrix metalloproteinase inhibition:

Data Source

PatentUS8455021B2Composition for prophylaxis or treatment of urinary system infection and method thereof
Publication Date: 2013.06.04 LIN CHIH HSIUNG

AI summary

The present invention relates to a method of reducing risk of recurrent urethritis or recurrent cystitis comprises administering to a patient with risk of recurrent urethritis or recurrent cystitis an effective amount of a composition consisting essentially of astilbin and chlorogenic acid.